EMG
NVCR icon

ETF Managers Group’s NovoCure NVCR Stock Holding History

ETF Managers Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$3.08M Buy
+51,133
New +$4.09M 0.1% 132
2022
Q4 		– Sell
-49,367
Closed -$3.75M – 642
2022
Q3 		$3.75M Buy
49,367
+3,724
+8% +$290K 0.12% 125
2022
Q2 		$3.31M Sell
45,643
-15,052
-25% -$1.13M 0.1% 137
2022
Q1 		$5.1M Sell
60,695
-4,760
-7% -$351K 0.1% 134
2021
Q4 		$5.22M Sell
65,455
-3,443
-5% -$346K 0.1% 158
2021
Q3 		$8M Sell
68,898
-4,748
-6% -$718K 0.15% 134
2021
Q2 		$16.5M Sell
73,646
-9,646
-12% -$1.88M 0.27% 114
2021
Q1 		$10.4M Buy
83,292
+14,875
+22% +$2.35M 0.19% 123
2020
Q4 		$11.9M Sell
68,417
-30,172
-31% -$4.13M 0.26% 105
2020
Q3 		$10.7M Buy
98,589
+7,668
+8% +$613K 0.34% 94
2020
Q2 		$5.25M Buy
90,921
+7,118
+8% +$468K 0.19% 104
2020
Q1 		$5.87M Buy
83,803
+7,448
+10% +$589K 0.27% 89
2019
Q4 		$6.51M Buy
76,355
+8,005
+12% +$646K 0.23% 94
2019
Q3 		$5.02M Buy
68,350
+7,200
+12% +$576K 0.18% 91
2019
Q2 		$3.72M Buy
61,150
+10,238
+20% +$519K 0.12% 97
2019
Q1 		$2.45M Sell
50,912
-4,875
-9% -$235K 0.12% 89
2018
Q4 		$1.87M Buy
55,787
+3,420
+7% +$125K 0.09% 127
2018
Q3 		$2.74M Buy
+52,367
New +$2.08M 0.1% 106
2018
Q2 		– Sell
-41,049
Closed -$835K – 565
2018
Q1 		$835K Buy
41,049
+6,760
+20% +$145K 0.05% 179
2017
Q4 		$696K Buy
34,289
+8,929
+35% +$172K 0.05% 169
2017
Q3 		$503K Buy
25,360
+1,755
+7% +$34.5K 0.04% 98
2017
Q2 		$408K Buy
+23,605
New +$305K 0.03% 89

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $652M AUM 36.81% 1-Year Est. Return

ETF Managers Group's NVCR Position: Q1 2023 in Review

ETF Managers Group opened a new position in NovoCure (NVCR) in Q1 2023: 51,133 shares worth $3.08M. The stake represents 0.1% of the portfolio and ranks #132 among its holdings. This is a return to the name: ETF Managers Group previously reported a position in NVCR as recently as Q3 2022.

ETF Managers Group first reported a position in NVCR in Q2 2017 and has held it in 22 quarters since. The position peaked at $16.5M in Q2 2021. 296 funds tracked by Wall St. Rank hold NVCR as of Q1 2023.

  • ETF Managers Group held 51,133 shares of NovoCure worth $3.08M as of Q1 2023.
  • NovoCure was a new ETF Managers Group position in Q1 2023.
  • NovoCure made up 0.1% of ETF Managers Group's portfolio in Q1 2023, its #132 holding.
  • ETF Managers Group first reported a position in NovoCure in Q2 2017 and has held it in 22 quarters since.
  • ETF Managers Group's NovoCure position peaked at $16.5M in Q2 2021.
  • 296 funds tracked by Wall St. Rank held NovoCure as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.